Executive Order 12866

This amendment does not meet the criteria of a ''significant regulatory action'' as described in E.O. 12866.

Drafting Information: The principal author of this document was Keith B. Rudich, Esq., Regulations Branch, Office of Regulations and Rulings, U.S. Customs Service. However, personnel from other offices participated in its development.

List of Subjects in 19 CFR Part 12

Customs duties and inspections, Imports, Cultural property.

Amendment to the Regulations

Accordingly, Part 12 of the Customs Regulations (19 CFR Part 12) is amended as set forth below:

PART 12—[AMENDED]

1. The general authority and specific authority citation for Part 12, in part, continue to read as follows:

Authority: 5 U.S.C. 301, 19 U.S.C. 66, 1202 (General Note 20, Harmonized Tariff Schedule of the United States (HTSUS)), 1624;

* * * * *

Sections 12.104 through 12.104i also issued under 19 U.S.C. 2612;

* * * * *

§ 12.104 [Amended]

2. In § 12.104g, paragraph (a) the list of agreements imposing import restrictions on described articles of cultural property of State Parties is amended by adding Guatemala in appropriate alphabetical order as follows:

State	Cultural property	T.D. No.
* *	* * * * *	*
Guatemala	Archaeological Material From Sites In The Peten Lowlands Of Guatemala, And Related Pre-Columbian Material From The Highlands And The Southern Coast of Guatemala.	T.D. 97—81
* *	* * * * *	*

3. In § 12.104(g), paragraph (b), the list of emergency actions imposing import restrictions on described articles of cultural property of State parties is amended by removing the entry for ''Guatemala'' in its entirety.

Approved: September 29, 1997.

Samuel H. Banks,

Acting Commissioner of Customs.

John P. Simpson,

Deputy Assistant Secretary of the Treasury.

[FR Doc. 97–26219 Filed 10–2–97; 8:45 am]

BILLING CODE 4820–02–P

DEPARTMENT OF THE TREASURY

Customs Service

19 CFR Part 24

[T.D. 97–45]

RIN 1515–AA57

Update of Ports Subject to the Harbor Maintenance Fee; Corrections

AGENCY: Customs Service, Treasury.

ACTION: Interim regulations; corrections.

SUMMARY: This document corrects an omission that was made in the interim regulations document published in the **Federal Register** on June 4, 1997, which updated the list of ports that process commercial vessels that transport cargo that are subject to the Water Resources Development Act of 1986.

DATES: This correction is effective October 3, 1997.

FOR FURTHER INFORMATION CONTACT: Patricia Barbare, Office of Finance, (202) 927–0034.

SUPPLEMENTARY INFORMATION:

Background

On June 4, 1997, Customs published in the **Federal Register** (62 FR 30448) interim regulations (T.D. 97–45) which amended § 24.24 of the Customs Regulations (19 CFR 24.24) to update the list of ports that process commercial vessels that transport cargo that are subject to the Water Resources Development Act of 1986. A correction document to these interim regulations was published in the **Federal Register** (62 FR 45156) on August 26, 1997. Since then, it has come to Customs' attention that the June 4 document contains another error. The interim rule document failed to list under the Galveston Bay Ports the ports of Galveston and Texas City and their port codes: 5310 and 5306, respectively. Accordingly, this document corrects that omission.

Corrections to Publication

The document (FR Doc. 97–14409) published in the **Federal Register** (62 FR 30448) on June 4, 1997, is corrected as follows:

1. On page 30453, under the heading for ''Texas'', in the fourth line, the listing ''Galveston Bay Ports* '' should read as follows:

Port code, port name and state	Port descriptions and notations
* * * * *	
Texas	
* * * * *	
Galveston Bay Ports* 5310—Galveston ..... 5306—Texas City	Includes Port Bolivar and all points on Galveston Bay in Galveston County. Movements between points within this area are intraport.
* * * * *	

Dated: September 29, 1997.

Harold M. Singer,

Chief, Regulations Branch.

[FR Doc. 97–26218 Filed 10–2–97; 8:45 am]

BILLING CODE 4820–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[DEA No. 161F]

Schedules of Controlled Substances: Excluded Veterinary Anabolic Steroid Implant Products

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final rule.

SUMMARY: The interim rule (62 FR 29289, May 30, 1997) which identified eight veterinary anabolic steroid implant products as being excluded

from the Controlled Substances Act (CSA) (21 U.S.C. 801 *et seq.*) is adopted without change.

DATES: *Effective Date:* October 3, 1997.

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, 202–307–7183.

SUPPLEMENTARY INFORMATION: The Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA), published in the **Federal Register**, an interim rule which identified eight products as being excluded veterinary anabolic steroid implant products (62 FR 29289, May 30, 1997). Comments were requested, none were received.

Therefore, pursuant to the authority delegated to the Administrator of the DEA pursuant to 21 U.S.C. 871(a) and 28 CFR 0.100 and redelegated to the Deputy Assistant Administrator of the Drug Enforcement Administration Office of Diversion Control, pursuant to 28 CFR 0.104, appendix to subpart R, section 7(g), the Deputy Assistant Administrator of the Office of Diversion Control hereby adopts as a final rule, without change, the interim rule amending the products which are described in 21 CFR 1308.26 which was published at 62 FR 29289 on May 30, 1997.

The veterinary anabolic steroid implant products which are described in 21 CFR 1308.26 are excluded from application of the CSA in relation to their production, distribution, and use in animals only. If any person distributes, dispenses or otherwise diverts these products to use in humans, he/she shall be deemed to have distributed a Schedule III controlled substance and may be prosecuted for CSA violations. The veterinary anabolic steroid implants products which are excluded from application of the CSA are as follows:

EXCLUDED VETERINARY ANABOLIC STEROID IMPLANT PRODUCTS

Trade name	Company	NDC or DIN No.	Delivery system	Ingredients	Quantity
Component E–H	Vetlife, Inc., Norcross, GA	021641–002	20 implant belt, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Component E–H	Elanco, Scarborough, ON	01968327	20 implant belt, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Component TE–S	VetLife, Inc., Norcross, GA.	021641–004	20 implant belt, 6 pellets/implant.	Trenbolone acetate	120 mg/implant (20 mg/pellet)
				Estradiol	24 mg/implant (4 mg/pellet)
Component T–H	VetLife, Inc., Norcross, GA.	021641–006	20 implant belt, 10 pellets/implant.	Trenbolone acetate	200 mg/implant (20 mg/pellet)
Component T–S	VetLife, Inc., Norcross, GA.	021641–005	20 implant belt, 7 pellets/implant.	Trenbolone acetate	140 mg/implant (20 mg/pellet)
F–TO	Animal Health, Upjohn International, Kalamazoo, MI.	00093351	20 implant cartridge belt, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Oestradiol benzoate	20 mg/implant (2.5 mg/pellet)
Finaplix-H	Hoechst Roussel Vet, Somerville, NJ.	12799–807–10	10 implant cartridge, 10 pellets/implant.	Trenbolone acetate	200 mg/implant (20 mg/pellet)
Finaplix-S	Hoechst Roussel Vet, Somerville, NJ.	12799–807–07	10 implant cartridge, 7 pellets/implant.	Trenbolone acetate	140 mg/implant (20 mg/pellet)
Heifer-oid	Anchor Division, Boehringer Ingelheim, St. Joseph, MO.	.....	Single & 20 implant cartridge belts, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Heifer-oid	Bio-Ceutic Division, Boehringer Ingelheim, St. Joseph, MO.	.....	20 implant cartridge belt, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Heifer-oid	Ivy Laboratories, Inc., Overland Park, KS.	.....	Single & 20 implant cartridge belts, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Implus-H	The Upjohn Co., Kalamazoo, MI.	0009–0434–01	20 implant cartridge belt, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Implus-H	Upjohn Co., Animal Health Div., Orangeville, ON.	06–0434–01 01968327	20 implant cartridge belt, 8 pellets/implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Revalor-G	Hoechst Roussel Vet, Somerville, NJ.	12799–811	10 implant cartridge 2 pellets/implant.	Trenbolone acetate	40 mg/implant (20 mg/pellet)
				Estradiol	4 mg/implant (2 mg/pellet)

EXCLUDED VETERINARY ANABOLIC STEROID IMPLANT PRODUCTS—Continued

Trade name	Company	NDC or DIN No.	Delivery system	Ingredients	Quantity
Revalor-H	Hoechst Roussel Vet, Somerville, NJ.	12799–810	10 implant cartridge, 7 pellets/implant.	Trenbolone acetate	140 mg/implant (20 mg/pellet)
				Estradiol	14 mg/implant (2 mg/pellet)
Revalor-S	Hoechst Roussel Vet, Somerville, NJ.	12799–809	10 implant cartridge, 6 pellets/implant.	Trenbolone acetate	120 mg/implant (20 mg/pellet)
				Estradiol	24 mg/implant 4 mg/pellet)
Synovex H	Fort Dodge Labs, Fort Dodge, IA.	0856–3901	10 implant clip, 8 pellets/ implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Synovex H	Syntex Laboratories, Palo Alto, CA.	.....	10 implant clip, 8 pellets/ implant.	Testosterone propionate	200 mg/implant (25 mg/pellet)
				Estradiol benzoate	20 mg/implant (2.5 mg/pellet)
Synovex Plus	Fort Dodge Labs, Fort Dodge, IA.	0856–3904	10 implant clip, 8 pellets/ implant.	Trenbolone acetate	200 mg/implant (25 mg/pellet)
				Estradiol	28 mg/implant (3.5 mg/pellet)

In accordance with the provisions of 21 U.S.C. 811(a) of the CSA, this action is a formal rulemaking ''on the record after opportunity for a hearing.'' Such proceedings are conducted pursuant to the provisions of 5 U.S.C. 556 and 557 and, as such, are exempt from review by the Office of Management and Budget pursuant to Executive Order (E.O.) 12866, section 3(d)(1).

The Deputy Assistant Administrator, Office of Diversion Control, in accordance with the Regulatory Flexibility Act [5 U.S.C. 605(b)], has reviewed this rule and by approving it certifies that it will not have a significant economic impact on a substantial number of small-business entities. The inclusion of a product in 21 CFR 1308.26 relieves persons who handle the product in the course of legitimate business from the requirements imposed by the CSA.

This rule will not result in the expenditure by State, local and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more in any one year, and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under provisions of the Unfunded Mandates Reform Act of 1995.

This rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This rule will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices; or have significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of the United States-based companies to complete with foreign-based companies in domestic and export markets.

This rule will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with E.O. 12612, it is determined that this rule will not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

Dated: September 8, 1997.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 97–25973 Filed 10–2–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[DEA No. 160F]

Schedules of Controlled Substances: Exempt Anabolic Steroid Products

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final rule.

SUMMARY: The interim rule (62 FR 29288, May 30, 1997) which identified ten anabolic steroid products as being exempt from certain regulatory provisions of the Controlled Substances Act (CSA) (21 U.S.C. 801 *et seq.*) is adopted without change.

DATES: *Effective Date:* October 3, 1997.

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, 202–307–7183.

SUPPLEMENTARY INFORMATION: The Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA), published in the **Federal Register,** an interim rule which identified ten products as being exempt anabolic steroid products (62 FR 29288, May 30, 1997). Comments were requested, none were received.

Therefore, pursuant to the authority delegated to the Administrator of the DEA pursuant to 21 U.S.C. 871(a) and 28 CFR 0.100 and redelegated to the Deputy Assistant Administrator of the Drug Enforcement Administration Office of Diversion Control, pursuant to 28 CFR 0.104, appendix to subpart R, section 7(g)9, the Deputy Assistant Administrator of the Office of Diversion Control, hereby adopts as a final rule, without change, the interim rule amending 21 CFR 1308.34 which was published at 62 FR 29288 on May 30, 1997.

The anabolic steroid containing compounds, mixtures, or preparations which are described in 21 CFR 1308.34 are as follows: